Non-Small Cell Lung Cancer
The research portfolio is centered on completely resected primary stage IB, stage II, and stage IIIA non-small cell lung cancer, with interest in patients whose tumors show PD-L1 expression and lack EGFR and ALK alterations.
- Adjuvant treatment after complete resection
- PD-L1–selected lung cancer populations
- Early-stage and locally advanced disease
Work in this area reflects a focus on postoperative disease control and outcomes in surgically treated lung cancer.
Immuno-Oncology
The sponsor supports research in immune-based cancer therapy for lung malignancy, with attention to treatment strategies intended to reduce recurrence risk after surgery.
- Checkpoint-directed therapy
- Tumor immune-marker selection
- Maintenance of disease-free survival
Its clinical interest lies in evaluating immune-targeted approaches within a defined thoracic oncology setting.
Thoracic Oncology
Clinical activity is concentrated in lung cancer, especially the management of patients following surgical removal of their primary tumor, where recurrence prevention remains a major concern.
- Resected lung cancer
- Postoperative oncologic management
- Localized and regionally advanced disease
This area connects surgical oncology with systemic treatment strategies for non-small cell lung cancer.
Biomarker-Defined Cancer Care
The funded research includes a biomarker-informed approach using PD-L1 status and exclusion of EGFR and ALK alterations to identify a specific treatment population.
- PD-L1 testing
- Molecular subtype selection
- Targeted patient stratification
These interests place emphasis on matching oncology treatment choices to tumor characteristics.
